Prostvac + ipilimumab shows promise in management of mCRPC

Results from a small trial of Barvarian Nordic’s investigational drug Prostvac — used in combination with Bristol-Myers Squibb’s ipilimumab (Yervoy) — appear to have shown relatively dramatic effects in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Two new drugs recommended for approval in Europe

Two drugs already approved in the US that either have been or may be used in the treatment of prostate cancer have now been recommended for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). … READ MORE …

US FDA approves ipilimumab

The U.S. Food & Drug Administration today approved ipilimumab (brand name  Yervoy®) for the treatment of patients with metastatic melanoma (an aggressive form of skin cancer). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,342 other followers